ВОЗМОЖНОСТИ ПОЗИТРОННО-ЭМИССИОННОЙ ТОМОГРАФИИ В ДИАГНОСТИКЕ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ ГОЛОВНОГО МОЗГА (обзор литературы)

Igor Mikhaylovich Ivashchenko, Pavel Gennadevich Shnyakin, Anna Andreevna Kataeva, Irina Sergeevna Pavlova, Knarik Vrezhovna Grigoryan, Mariya Andranikovna Shirvanyan


Аннотация


В диагностике новообразований на дооперационном и послеоперационном этапах позитронно-эмиссионная томография (ПЭТ) является самым информативным методом лучевой диагностики, основным преимуществом которого является определение не только структуры и локализации опухолей (как в случае МРТ – магнитно-резонансная томография и МСКТ – мультиспиральная компьютерная томография), но также и метаболических процессов в них, что дает возможность диагностировать опухолевый процесс на самых ранних сроках, а также разграничить продолженный рост опухоли от псевдопрогрессии на фоне постлучевых некрозов. В настоящее время существует достаточно широкий спектр радиофармпрепаратов, используемых для ПЭТ, при этом наибольшее клиническое значение находят 18F-ФДГ и 11С-МЕТ (18F-фтордиоксиглюкоза и 11С-метионин). В представленном обзоре описывается место позитронно-эмиссионной томографии в диагностике злокачественных опухолей головного мозга, а также указывается на чувствительность разных радиофармпрепаратов при разной патологии головного мозга, что имеет важное значение при все более широком внедрении данного метода диагностики в клиническую практику.

Ключевые слова


ПЭТ; глиальные опухоли; радиофармпрепарат

Полный текст:

PDF>PDF

Литература


Andreas H. Jacobs A.H., Thomas, A. Lutz W. Kracht L.W., Li H., Dittmar C., Garlip G., Galldiks N., MD1, Klein J.C., Sobesky J., Hilker R., Vollmar S., Herholz K., Wienhard K., Wolf-Dieter Heiss. W.D. 18F-Fluoro-L-Thymidine and 11C-Methylmethionine as Markers of Increased Transport and Proliferation in Brain Tumors. Journal of nuclear medicine, 2005, vol. 46, no. 12.

Berntsson S.G., Falk A., Savitcheva I., Godau A., Zetterling M., Hesselager G., Alafuzoff I., Larsson E.M., Smits A. Perfusion and diffusion MRI combined with 11C-methionine PET in the preoperative evaluation of suspected adult low-grade gliomas. J Neurooncol, 2013, vol. 114, no. 2, pp. 241–249.

Brandsma D., Stalpers L., Taal W., Sminia P., van den Bent M.J. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol, 2008, vol. 9, no. 5, pp. 453–461.

Charnley N., West C.M., Barnett C.M., Brock C., Bydder G.M., Glaser M., Newlands E.S., Swindell R., Matthews J., Price P. Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. Int J Radiat Oncol Biol Phys, 2006, vol. 66, pp. 331–338.

Chen W. Clinical Applications of PET in Brain Tumors. J Nucl Med, 2007, vol. 48, no. 9, pp. 1468–1481.

Floeth F.W., Pauleit D., Sabel M., Stoffels G., Reifenberger G., Riemenschnei­der M.J., Jansen P., Coenen H.H., Steiger H.J., Langen K.J. Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med, 2007, vol. 48, pp. 519–527.

Fougère С., Suchorska B., Bartenstein P., Kreth F.W., Tonn J.C. Molecular im-aging of gliomas with PET: opportunities and limitations. Neuro Oncol, 2011, vol.13, no. 8, pp. 806–819.

Galldiks N, Ullrich R, Schroeter M., Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Eur J Nucl Med Mol Imaging, 2010, vol. 37, pp. 84–92.

Galldiks N., Langen K.J., Pope W.B. From the clinician’s point of view – what is the status quo of positron emission tomography in patients with brain tumors. Neuro Oncol, 2015, vol. 17, no. 11, pp. 1434–1444.

Galldiks N., Ullrich R., Schroeter M., Fink G.R., Kracht L.W., Imaging biological activity of a glioblastoma treated with an individual patient-tailored, experimental therapy regimen. J Neurooncol, 2009, vol. 93, no. 3, pp. 425–430.

Glaudemans A.W., Enting R.H., Heesters M.A., Dierckx R.A., van Rheenen R.W., Walenkamp A.M., Slart R.H. A large retrospective single-centre study to define the best image acquisition protocols and interpretation criteria for white blood cell scintigraphy with Tc-99m-HMPAO-labelled leucocytes in musculoskeletal infections. Eur J Nucl Med Mol Imaging, 2013, vol. 40, no. 11, pp. 1760–1769.

Grosu A.L., Piert M., Weber W.A., Jeremic B., Picchio M., Schratzenstaller U., Zimmermann F.B., Schwaiger M., Molls M. Positron emission tomography for radiation treatment planning. Strahlenther Onkol. 2005, vol. 181, pp. 483–499.

Grosu A.L., Weber W.A., Riedel E., Jeremic B., Nieder C., Franz M., Gumprecht H., Jaeger R., Schwaiger M., Molls M. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys, 2005, vol. 63, pp. 64–74.

Huang Z., Zuo C., Guan Y., Zhang Z., Liu P., Xue F., Lin X. Misdiagnoses of 11C-choline combined with 18F-FDG PET imaging in brain tumours. Nucl Med Commun, 2008, vol. 29, pp. 354–358.

Jacobs A.H., Kracht L.W., Gossmann A., Rüger M.A., Thomas A.V., Thiel A., Herholz K. Imaging in neurooncology. NeuroRx. 2005, vol. 2, pp. 333–347.

Kato T., Shinoda J., Nakayama N., Miwa K., Okumura A., Yano H., Yoshimura S., Maruyama T., Muragaki Y., Iwama T. Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol, 2008, vol. 29, no. 6, pp. 1176–82.

Lee I.H., Piert M., Gomez-Hassan D., Junck L., Rogers L., Hayman J., Ten Haken R.K., Lawrence T.S., Cao Y., Tsien C. Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 2009, vol. 73, pp. 479–485.

Mehrkens J.H., Popperl G., Rachinger W., Herms J., Seelos K., Tatsch K., Tonn J.C., Kreth F.W. The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. J Neurooncol. 2008, vol. 88, pp. 27–35.

Miwa K., Matsuo M., Shinoda J., Yokoyama K, Kato T., Okumura A., Ueda T., Yamada J., Yano H., Iwama T. Re-irradiation of recurrent glioblastoma multiforme using 11C-methionine PET/CT/MRI image fusion for hypofractionated stereotactic radiotherapy by intensity modulated radiation therapy. Radiat Oncol. 2014, vol. 9, pp. 181.

Miwa K., Shinoda J., Yano H., Okumura A., Iwama T., Nakashima T., Sakai N. Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry, 2004, vol. 75, pp. 1457–1462.

Nariai T., Tanaka Y., Wakimoto H., Aoyagi M., Tamaki M., Ishiwata K., et al. Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg, 2005, vol. 103, no. 3, pp. 498–507.

Nojiri T, Nariai T, Aoyagi M, Senda M, Ishii K, Ishiwata K, Ohno. Contributions of biological tumor parameters to the incorporation rate of l-[methyl-11C] methionine into astrocytomas and oligodendrogliomas. J Neurooncol, 2009, vol. 93, no. 2, pp. 233-241.

Norbert Galldiks N., Lutz W. Kracht, Frank Berthold, Hrvoje Miletic, Johannes C. Klein, KarlHerholz, Andreas H. Jacobs, Wolf-Dieter Heiss. [11C]-l-Methionine positron emission tomography in the management of children and young adults with brain tumors. J Neurooncol, 2010, vol. 96, no. 2, pp. 231–239.

Padma M.V., Said S., Jacobs M., Hwang D.R., Dunigan K., Satter M., Christian B., Ruppert J., Bernstein T., Kraus G., Mantil J.C. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol, 2003, vol. 64, no. 3, pp. 227–237.

Pope W.B., Lai A., Nghiemphu P., Mischel P., Cloughesy T.F. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology, 2006, vol. 66, no. 8, pp. 1258–1260.

Singhal T., Narayanan T.K., Jacobs M.P., Bal C., Mantil J.C. 11C-methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI. Journal of Nuclear, 2012, vol. 53, no. 11, pp. 1709–1715.

Stockhammer F, Misch M, Horn P, Koch A, Fonyuy N, Plotkin M. Association of F18-fluoro-ethyl-tyrosin uptake and 5-aminolevulinic acid-induced fluorescence in gliomas. Acta Neurochir (Wien), 2009, vol. 151, pp. 1377–1383.

Tabatabai G, Stupp R, van den Bent M.J., Hegi M.E., Tonn J.C., Wick W., Weller M. Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol. 2010, vol. 120, no. 5, pp. 585–592.

Terakawa Y., Tsuyuguchi N., Iwai Y., Yamanaka K., Higashiyama S., Takami T., Ohata K. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med. 2008, vol. 49, no. 5, pp. 694–699.

Tsien C., Brown D., Normolle D., Schipper M., Morand P., Junck L., Heth J., Gomez-Hassan D., TenHaken R., Chenevert T., Cao Y., Lawrence T. Concurrent Temozolomide and Dose-Escalated Intensity Modulated Radiation Therapy in Newly Diagnosed Glioblastoma. Clinical Cancer Research, 2012, vol. 18, no. 1, pp. 273–279.

Ullrich R.T., Kracht L., Brunn A., Herholz K., Frommolt P., Miletic H., Deckert M., Heiss W.D., Jacobs A.H. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med, 2009, vol. 50, no. 12, pp. 1962–1968.

Van Laere K1, Ceyssens S., Van Calenbergh F., de Groot T., Menten J., Flamen P., Bormans G., Mortelmans L. Direct of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value, Eur J Nucl Med Mol Imaging. 2005, vol. 32, no. 1, pp. 39–51.

Weller M., Cloughesy T., Perry J.R., Wick W. Standards of care for treatment of recurrent glioblastoma – are we there yet. Neuro Oncol, 2013, vol. 15, no. 1, pp. 4–27.

Wen P.Y., Macdonald D.R., Reardon D.A., Cloughesy T.F., Sorensen A.G., Galanis E., Degroot J., Wick W., Gilbert M.R., Lassman A.B., Tsien C., Mikkelsen T., Wong E.T., Chamberlain M.C., Stupp R., Lamborn K.R., Vogelbaum M.A., van den Bent M.J., Chang S.M. Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol, 2010, vol. 28, no. 11, pp. 1963–1972.

Yamaguchi S., Terasaka S., Kobayashi H., Narita T., Hirata K., Shiga S., Usui R., Tanaka S., Kubota K., Murata J., Asaoka K. Combined use of positron emission tomography with (18)F-fluorodeoxyglucose and (11)C-methionine for preoperative evaluation of gliomas. No Shinkei Geka. 2010, vol. 38, no. 7, pp. 621–628.

Yang I., Aghi M.K. New advances that enable identification of glioblastoma recurrence. Nat Rev Clin Oncol, 2009, vol. 6, pp. 648–657.

Tyutin L.A., Stanzhevskiy A.A., Panfilenko A.F., Kostenikov N.A., Ilyushchenko Yu.R. Vozmozhnosti ispolzovaniya metodov molekulyarnoy vizualizatsii s kompleksom sovremennykh radiofarmatsevticheskikh preparatov v neyroonkologii [Possibilities of using molecular imaging methods with a complex of modern radiopharmaceuticals in neurooncology]. Voprosy onkologii [Problems in oncology]. 2013, vol. 59, no. 4, pp. 420–427.

Granov A.M., Tyutin L.A., Stanzhevskiy A.A. Primenenie tekhnologiy yadernoy meditsiny v nevrologii, psikhiatrii i neyrokhirurgii [Application of nuclear medicine technologies in neurology, psychiatry and neurosurgery]. Vestnik RAMN [Annals of the Russian Academy of Medical Sciences]. 2012, no. 9: pp. 13–18.

Zhuravleva A, Shershever A. S., Bentsion D. L. Vozmozhnosti perfuzionnoy KT v otsenke rezul’tatov kombinirovannogo i kompleksnogo lecheniya gliom golovnogo mozga [Possibilities of perfusion CT in the evaluation of the results of combined and complex treatment of brain gliomas]. Luchevaya diagnostika i terapiya [Radiation diagnosis and therapy]. 2012, no. 2, pp. 81–84.

Marusina M.Ya., Kaznacheeva A.O. Sovremennye vidy tomografii [Modern types of tomography] Ucheb. posobie. SPb: SPbGU ITMO, 2006. 132 p.

Trofimova T.N., Trofimov E. A. Sovremennye strategii luchevoy diagnostiki pri pervichnykh opukholyakh golovnogo mozga [Modern strategies of radiation diagnosis in primary brain tumors ]. Prakticheskaya onkologiya [Practical oncology], 2013, vol. 14, no. 3, pp. 141–147.




DOI: https://doi.org/10.12731/wsd-2018-4-72-87

Ссылки

  • На текущий момент ссылки отсутствуют.




(c) 2018 Igor Mikhaylovich Ivashchenko, Pavel Gennadevich Shnyakin, Anna Andreevna Kataeva, Irina Sergeevna Pavlova, Knarik Vrezhovna Grigoryan, Mariya Andranikovna Shirvanyan

Лицензия Creative Commons
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.

ISSN 2072-0831 (print)

ISSN 2307-9428 (online)

                              

Контент доступен под лицензией Creative Commons Attribution-NonCommercial-NoDerivs 4.0.

HotLog Яндекс цитирования